Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00833508

Enrollment

Registered

2009-02-02

Start date

2009-01-31

Completion date

2011-10-31

Last updated

2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Exercise capacity, Chemoradiotherapy, Colorectal cancer

Brief summary

This study will investigate the effect of preoperative chemoradiotherapy on exercise capacity as measured by cardiopulmonary exercise testing in patients with colorectal cancer.

Detailed description

Chemoradiotherapy is associated with adverse effects. Patients with certain colorectal cancers undergo chemoradiotherapy prior to surgical resection. We intend to assess patient exercise capacity before and after chemoradiotherapy to assess whether this deteriorates. If there is a deleterious effect, this may affect operative outcome.

Interventions

OTHERCardiopulmonary exercise testing

Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age greater than 65 * Colorectal cancer requiring preoperative chemoradiotherapy

Exclusion criteria

* Inability to walk, or exercise on a bicycle or treadmill * Inability to understand instructions for CPET testing * ASA grade 4 or 5 (indicating severe cardiovascular co-morbidity and not expected to survive surgery) * Contraindications to Exercise Testing * Myocardial infarction occurring 10 days or less before CPX testing * Symptomatic arrythmias * Left Main Stem coronary disease of \>50% * Severe hypertension (SBP\>180mmHg) * Resting SpO2 \<85% * Acute cardiac inflammatory conditions (myocarditis, pericarditis) * Unstable angina with symptoms within 4 days * Dissecting aneurysm of aorta * Acute pyrexial illness * Thyrotoxicosis * Syncopal episodes * Lower limb thrombosis (arterial or venous)

Design outcomes

Primary

Measure	Time frame
Change of Anaerobic threshold of 1.5ml/min/kg or more	6 weeks

Secondary

Measure	Time frame
Operative outcome	6-10 weeks

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026